Trials / Completed
CompletedNCT02534506
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Urelumab | |
| DRUG | Nivolumab |
Timeline
- Start date
- 2015-11-06
- Primary completion
- 2016-11-11
- Completion
- 2016-11-11
- First posted
- 2015-08-27
- Last updated
- 2020-05-18
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02534506. Inclusion in this directory is not an endorsement.